Results 251 to 260 of about 838,579 (399)

Factors associated with cardiovascular events after simultaneous liver–kidney transplant from the US Multicenter Simultaneous Liver–Kidney Transplant Consortium

Hepatology Communications, EarlyView., 2022
Abstract Cardiovascular disease is a leading complication after both liver and kidney transplantation. Factors associated with and rates of cardiovascular events (CVEs) after simultaneous liver–kidney transplant (SLKT) are unknown. This was a retrospective cohort study of adult SLKT recipients between 2002 and 2017 at six centers in six United Network ...
Jennifer Jo, Gonzalo Crespo, Dyanna Gregory, Jasmine Sinha, Jiaheng Xie, Min Zhang, John Magee, Pranab Barman, Yuval A. Patel, Aaron Schluger, Kara Walters, Scott Biggins, Natalia Filipek, Giuseppe Cullaro, Randi Wong, Jennifer C. Lai, Gabriel J. Perreault, Elizabeth C. Verna, Pratima Sharma, Lisa B. VanWagner   +19 more
wiley   +1 more source

Cholestasis in hepatitis E virus infection. [PDF]

World J Hepatol
Kanda T, Sasaki-Tanaka R, Yokoo T, Hayashi K, Kamimura H, Tsuchiya A, Terai S.   +6 more
europepmc   +1 more source

Pharmacokinetics, Safety, and Skin Irritation and Sensitization Potential of Clascoterone Cream in Early‐Phase Clinical Study Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Clascoterone is an androgen receptor inhibitor approved for the treatment of acne vulgaris in patients 12 years of age and older. Here, we report results of 5 phase 1 studies that assessed the pharmacokinetics (PK), safety, and skin irritation and sensitization potential of clascoterone cream 1% in healthy participants and patients with acne ...
Andrea Francesco Daniele Di Stefano, Milko Massimiliano Radicioni, Gerhard Garhöfer, Martina Cartwright, Markus Müller, Iris Kopeloff, Luigi Moro, Nicholas Squittieri, Alessandro Mazzetti   +8 more
wiley   +1 more source

Research Progress on Hepatitis E Virus Culture. [PDF]

Pathogens
Zhang J, Liang Z, Liu F, Wang Y, Huang W, Nie J.   +5 more
europepmc   +1 more source

In VitroInfection and Replication of Hepatitis E Virus in Primary Cynomolgus Macaque Hepatocytes

, 1997
Albert W. Tam, Richard White, Patrice O. Yarbough, Brendan Murphy, C. Patrick McAtee, Robert E. Lanford, Thomas R. Fuerst   +6 more
openalex   +1 more source

Populations Addressed in Vaccines Approved via the European Medicines Agency

Clinical Pharmacology &Therapeutics, EarlyView.
Therapeutic and prophylactic agents require robust evidence before patient use. Randomized controlled trials are essential for evaluating safety and efficacy but often exclude specific populations that are also targets for the intervention. This study assessed which populations are included in vaccine registration studies and/or addressed in label ...
Débora D. Gräf, Lukas Westphal, Jonathan Kimmelman, Christine E. Hallgreen   +3 more
wiley   +1 more source

Thermal Inactivation of Hepatitis E Virus: A Narrative Review. [PDF]

Viruses
Kanda T, Okamoto H.
europepmc   +1 more source

Hepatitis E virus ORF3 is a functional ion channel required for release of infectious particles

Proceedings of the National Academy of Sciences of the United States of America, 2017
Q. Ding, B. Heller, J. M. V. Capuccino, Bokai Song, Ila Nimgaonkar, G. Hrebikova, J. Contreras, A. Ploss   +7 more
semanticscholar   +1 more source

A serum exosomal microRNA‐based artificial intelligence diagnostic model for highly accurate detection of hepatocellular carcinoma

Cancer Communications, EarlyView.
Jin‐Seong Hwang, Sugi Lee, Gyeonghwa Kim, Hoibin Jeong, Kiyoon Kwon, Eunsun Jung, Yuna Roh, Taesang Son, Hana Lee, Moo‐Seung Lee, Kyoung‐Jin Oh, Hye Won Lee, Yu Rim Lee, Soo Young Park, Won Young Tak, Hyun Seung Ban, Hyun‐Soo Cho, Mi‐Young Son, Jang‐Seong Kim, Keun Hur, Dae‐Soo Kim, Tae‐Su Han   +21 more
wiley   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source